Group 1 - The article provides a list of companies and their respective activities related to shareholder meetings, new stock activities, performance announcements, and dividend distributions scheduled for October 30, 2025 [1][2][5][7]. - Several companies are mentioned as being in the process of initial public offerings (IPOs), including 旺山旺水-B, 均胜电子, 文远知行-W, and 赛力斯 [6]. - Companies such as 美的集团 and 翰森制药 are noted for their dividend distribution dates, indicating ongoing shareholder returns [7][8]. Group 2 - The article highlights the resumption of trading for companies like 舍图控股, 鸿盛昌资源, and 安能物流, suggesting a return to market activity after previous suspensions [6][7]. - The document lists various companies involved in dividend payouts, which may attract investor interest due to potential income generation [8]. - The presence of multiple companies in the IPO stage indicates a potentially active market environment for new investments [6].

Core Viewpoint - The company, Tengsheng Bo Pharmaceutical-B (02137), announced the granting of stock options and restricted share units as part of its 2023 incentive plans [1] Group 1: Stock Options - The company granted a total of 10.1205 million stock options to 79 option grantees according to the terms of the 2023 stock option plan [1] Group 2: Restricted Share Units - The company awarded a total of 2.114 million restricted share units to 8 grantees under the 2023 restricted share unit plan [1]

格隆汇10月28日丨腾盛博药-B(02137.HK)宣布，于2025年10月28日，公司根据2023年购股权计划条款向 79名购股权受让人授出合共1012万份购股权，并根据2023年股份奖励计划条款向8名受限制股份单位受 让人授出合共211万份受限制股份单位。 ...

腾盛博药-B(02137)发布公告，于2025年10月28日，公司根据2023年购股权计划条款向79名购股权受让 人授出合共1012.05万份购股权，并根据2023年股份奖励计划条款向8名受限制股份单位受让人授出合共 211.4万份受限制股份单位。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Brii Biosciences Limited 騰盛博藥生物科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2137） 授出購股權及受限制股份單位 向購股權受讓人授出購股權的詳情載列如下： | 購股權受讓人的 | 於本集團擔任 | 授出的 | | --- | --- | --- | | 姓名或類別 | 的職位 | 購股權數目 | | Hong博士 | 本公司執行董 | 1,377,500 | | | 事、董事會主席 | | | | 兼首席執行官 | | | 李博士 | 本公司執行董 | 716,000 | | | 事、首席財務 | | | | 官、公司秘書及 | | | | 首席戰略官 | | | 本集團5名高級 | | 8,027,000 | | 管理人員及72名 | | | | 其他僱員 | | | | 總計： | | 10,120,500 | 背景 作為薪酬委員會批准及管理全公司薪酬 ...

Core Points - Company Tengsheng Bo Pharmaceutical-B (02137) announced the issuance of new shares or transfer of treasury shares as part of a share incentive plan, involving a total of 150,000 new shares to be granted to participants on October 27, 2025 [1] Summary by Category - **Company Announcement** - Tengsheng Bo Pharmaceutical-B will issue a total of 150,000 new shares as part of its share incentive plan [1] - The issuance is scheduled for October 27, 2025, and will involve granting shares or options to participants [1] - **Share Incentive Plan** - The plan aims to reward participants through the issuance of new shares [1] - This move is part of the company's strategy to align the interests of participants with those of shareholders [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 騰盛博藥生物科技有限公司 呈交日期： 2025年10月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02137 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | 事件 | | 已發行股份（不包括庫存股份）數 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02137 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,200,000,000 | USD | 0.000005 | USD | | 6,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 1,200,000,000 | USD | 0.000005 | USD | | 6,000 | 本月底法定/註冊股本總額： USD 6,000 第 1 頁 共 11 頁 v 1.1.1 FF301 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: ...

Core Viewpoint - Tengsheng Bo Pharmaceutical-B (02137) has seen a significant stock increase of over 8%, currently trading at HKD 2.28 with a transaction volume of HKD 24.33 million [1] Group 1: Company Overview - Tengsheng Bo Pharmaceutical focuses on infectious diseases and central nervous system disorders, advancing a product pipeline that includes multiple unique drug candidates [1] Group 2: Recent Developments - Guojin Securities has released a report highlighting several upcoming milestones for Tengsheng Bo Pharmaceutical related to Elebsiran, including: - The ENSURE study's fourth cohort: 48-week treatment completion data to be published at EASL 2025 - The ENSURE study's first to third cohorts: 24-week follow-up data published at EASL 2025 - The ENSURE study's fourth cohort: 24-week follow-up data - The ENRICH study: treatment completion data [1]

Core Viewpoint - Tengsheng Bo Pharmaceutical (02137) has seen a significant stock price increase, rising over 8% and currently trading at 2.28 HKD with a transaction volume of 24.33 million HKD, indicating strong market interest and confidence in the company's pipeline and upcoming milestones [1] Company Summary - Tengsheng Bo Pharmaceutical focuses on infectious diseases and central nervous system disorders, advancing a product pipeline that includes multiple unique drug candidates [1] - Guojin Securities has highlighted several upcoming milestones related to Elebsiran, which are expected to enhance the company's profile and market position [1] Research and Development Updates - In the first half of 2025, the ENSURE study's fourth cohort will have its 48-week treatment completion data published at EASL 2025 [1] - The ENSURE study's first to third cohorts will have their 24-week follow-up data presented at EASL 2025 [1] - The ENSURE study's fourth cohort will also present 24-week follow-up data, alongside the treatment completion data from the ENRICH study [1]